OBJECTIVE: To assess whether family history (FH) of Alzheimer disease (AD) alone influences AD biomarker abnormalities. DESIGN: Adult Children Study. SETTING: Washington University's Charles F. and Joanne Knight Alzheimer's Disease Research Center. PARTICIPANTS: A total of 269 cognitively normal middle- to older-aged individuals with and without an FH for AD. MAIN OUTCOME MEASURES: Clinical and cognitive measures, magnetic resonance imaging-based brain volumes, diffusion tensor imaging-based white matter microstructure, cerebrospinal fluid biomarkers, and molecular imaging of cerebral fibrillar amyloid with positron emission tomography using the [(11)C] benzothiazole tracer, Pittsburgh compound B. RESULTS: A positive FH for AD was associated with an age-related decrease of cerebrospinal fluid Aβ42; the ε4 allele of apolipoprotein E (APOE4) did not alter this effect. Age-adjusted cerebrospinal fluid Aβ42 was decreased for individuals with APOE4 compared with the level for those without, and the decrease was larger for individuals with a positive FH compared with the decrease for those without. The variation of cerebrospinal fluid tau and Pittsburgh compound B mean cortical binding potential increased by age. For individuals younger than 55, an age-related increase in mean cortical binding potential was associated with APOE4 but not FH. For individuals older than 55, a positive FH and a positive APOE4 implied the fastest age-related increase in mean cortical binding potential. A positive FH was associated with decreased fractional anisotropy from diffusion tensor imaging in the genu and splenium of the corpus callosum. CONCLUSION: Independent of APOE4, FH is associated with age-related change of several cerebrospinal fluid, Pittsburgh compound B, and diffusion tensor imaging biomarkers in cognitively normal middle- to older-aged individuals, suggesting that non- APOE susceptibility genes for AD influence AD biomarkers.
OBJECTIVE: To assess whether family history (FH) of Alzheimer disease (AD) alone influences AD biomarker abnormalities. DESIGN: Adult Children Study. SETTING: Washington University's Charles F. and Joanne Knight Alzheimer's Disease Research Center. PARTICIPANTS: A total of 269 cognitively normal middle- to older-aged individuals with and without an FH for AD. MAIN OUTCOME MEASURES: Clinical and cognitive measures, magnetic resonance imaging-based brain volumes, diffusion tensor imaging-based white matter microstructure, cerebrospinal fluid biomarkers, and molecular imaging of cerebral fibrillar amyloid with positron emission tomography using the [(11)C] benzothiazole tracer, Pittsburgh compound B. RESULTS: A positive FH for AD was associated with an age-related decrease of cerebrospinal fluid Aβ42; the ε4 allele of apolipoprotein E (APOE4) did not alter this effect. Age-adjusted cerebrospinal fluid Aβ42 was decreased for individuals with APOE4 compared with the level for those without, and the decrease was larger for individuals with a positive FH compared with the decrease for those without. The variation of cerebrospinal fluid tau and Pittsburgh compound B mean cortical binding potential increased by age. For individuals younger than 55, an age-related increase in mean cortical binding potential was associated with APOE4 but not FH. For individuals older than 55, a positive FH and a positive APOE4 implied the fastest age-related increase in mean cortical binding potential. A positive FH was associated with decreased fractional anisotropy from diffusion tensor imaging in the genu and splenium of the corpus callosum. CONCLUSION: Independent of APOE4, FH is associated with age-related change of several cerebrospinal fluid, Pittsburgh compound B, and diffusion tensor imaging biomarkers in cognitively normal middle- to older-aged individuals, suggesting that non- APOE susceptibility genes for AD influence AD biomarkers.
Authors: Claire E Sexton; Ukwuori G Kalu; Nicola Filippini; Clare E Mackay; Klaus P Ebmeier Journal: Neurobiol Aging Date: 2010-07-08 Impact factor: 4.673
Authors: M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris Journal: Neurology Date: 2006-08-08 Impact factor: 9.910
Authors: Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2009-02 Impact factor: 10.422
Authors: Denise Head; Randy L Buckner; Joshua S Shimony; Laura E Williams; Erbil Akbudak; Thomas E Conturo; Mark McAvoy; John C Morris; Abraham Z Snyder Journal: Cereb Cortex Date: 2004-04 Impact factor: 5.357
Authors: Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk Journal: J Med Chem Date: 2003-06-19 Impact factor: 7.446
Authors: John R Cirrito; Patrick C May; Mark A O'Dell; Jennie W Taylor; Maia Parsadanian; Jeffrey W Cramer; James E Audia; Jeffrey S Nissen; Kelly R Bales; Steven M Paul; Ronald B DeMattos; David M Holtzman Journal: J Neurosci Date: 2003-10-01 Impact factor: 6.167
Authors: L Mosconi; R Mistur; R Switalski; M Brys; L Glodzik; K Rich; E Pirraglia; W Tsui; S De Santi; M J de Leon Journal: Neurology Date: 2008-11-12 Impact factor: 9.910
Authors: Andrew J Aschenbrenner; David A Balota; Anne M Fagan; Janet M Duchek; Tammie L S Benzinger; John C Morris Journal: J Int Neuropsychol Soc Date: 2015-09 Impact factor: 2.892
Authors: O C Okonkwo; G Xu; N M Dowling; B B Bendlin; A Larue; B P Hermann; R Koscik; E Jonaitis; H A Rowley; C M Carlsson; S Asthana; M A Sager; S C Johnson Journal: Neurology Date: 2012-05-16 Impact factor: 9.910
Authors: Ozioma C Okonkwo; Guofan Xu; Jennifer M Oh; N Maritza Dowling; Cynthia M Carlsson; Catherine L Gallagher; Alex C Birdsill; Matthew Palotti; Whitney Wharton; Bruce P Hermann; Asenath LaRue; Barbara B Bendlin; Howard A Rowley; Sanjay Asthana; Mark A Sager; Sterling C Johnson Journal: Cereb Cortex Date: 2012-12-12 Impact factor: 5.357
Authors: Courtney L Sutphen; Mateusz S Jasielec; Aarti R Shah; Elizabeth M Macy; Chengjie Xiong; Andrei G Vlassenko; Tammie L S Benzinger; Erik E J Stoops; Hugo M J Vanderstichele; Britta Brix; Heather D Darby; Manu L J Vandijck; Jack H Ladenson; John C Morris; David M Holtzman; Anne M Fagan Journal: JAMA Neurol Date: 2015-09 Impact factor: 18.302
Authors: Denise Head; Julie M Bugg; Alison M Goate; Anne M Fagan; Mark A Mintun; Tammie Benzinger; David M Holtzman; John C Morris Journal: Arch Neurol Date: 2012-05
Authors: Rebecca L Koscik; Asenath La Rue; Erin M Jonaitis; Ozioma C Okonkwo; Sterling C Johnson; Barbara B Bendlin; Bruce P Hermann; Mark A Sager Journal: Dement Geriatr Cogn Disord Date: 2014-02-20 Impact factor: 2.959
Authors: Liang Wang; Catherine M Roe; Abraham Z Snyder; Matthew R Brier; Jewell B Thomas; Chengjie Xiong; Tammie L Benzinger; John C Morris; Beau M Ances Journal: Ann Neurol Date: 2012-10 Impact factor: 10.422